tuneTypical Dose
Short-course oral postoperative use only has meaningful evidence
Enzyme
Serrapeptase
Serratiopeptidase
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Most measurable effects occur over the first postoperative week.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Serrapeptase has limited short-term evidence for reducing postoperative swelling, but it is not a proven systemic anti-inflammatory or mucus-clearing supplement.
Serrapeptase is marketed for everything from pain to sinus congestion, but the best human data are much narrower. Small clinical trials suggest it may reduce postoperative swelling and trismus after dental or facial procedures. That does not validate broader claims for chronic inflammation, fibrosis, or respiratory mucus problems.
Serrapeptase is described as a proteolytic enzyme with anti-edema effects, but human evidence is largely limited to acute postoperative settings.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced postoperative swelling and trismus
Secondary Outcomes
- Weak evidence for broader systemic uses
Safety
Contraindications and Interactions
Contraindications
- Bleeding disorder
Side effects
- GI upset
Interactions
- Anticoagulants or antiplatelet drugs
Avoid if
- You want long-term systemic anti-inflammatory effects
Evidence
Study-level References
ser-SRC-001Randomized controlled trial
Sourceopen_in_newAl-Khateeb TH, et al. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial. BMC Oral Health. 2021. doi:10.1186/s12903-021-01466-8. PMID:33653320.
Population: Adults undergoing impacted third-molar surgery.
Dose protocol: Short-term postoperative serratiopeptidase after impacted third molar surgery
Key findings: Improved swelling and trismus versus control.
Notes: Best modern direct trial.
Paper content
This is the cleanest modern serrapeptase trial. It supports a narrow postoperative anti-edema effect rather than broad systemic claims.
ser-SRC-002Randomized controlled trial
Sourceopen_in_newKumbhar S, et al. Role of Serratiopeptidase and Dexamethasone in the Control of Postoperative Swelling. J Maxillofac Oral Surg. 2020. doi:10.1007/s12663-019-01286-2. PMID:32855925.
Population: Adults after third-molar surgery.
Dose protocol: Short-term postoperative use after third-molar surgery
Key findings: Reduced swelling after day 2.
Notes: Supportive trial.
Paper content
This trial supports the same narrow takeaway seen in other serrapeptase studies. The enzyme may reduce postoperative swelling during the first days after oral surgery.
ser-SRC-003Randomized clinical trial.
Sourceopen_in_newChandra RB, Selvarasu K, Krishnan M. Comparison of Efficacy of Combination of Bromelain, Rutocide, and Trypsin With Serratiopeptidase on Postoperative Sequelae Following Mandibular Third Molar Surgery: A Randomized Clinical Trial. Cureus. 2023;15(11):e48633. doi:10.7759/cureus.48633. PMID:38090449.
Population: Patients undergoing mandibular third molar extraction.
Dose protocol: Serratiopeptidase with diclofenac versus bromelain-trypsin-rutocide combination after third molar surgery for 5 days
Key findings: Bromelain combination showed less pain and better mouth opening than serratiopeptidase on both postoperative assessment days.
Notes: Suggests serratiopeptidase may be less effective than alternative proteolytic enzyme combinations.
Paper content
This randomized trial compared a bromelain-trypsin-rutocide combination with serratiopeptidase for managing post-surgical complications after third molar extraction. Pain perception was lower in the bromelain combination group on both postoperative assessment days. The bromelain combination also improved mouth opening more effectively than serratiopeptidase. The study suggests that serratiopeptidase may be less effective than alternative proteolytic enzyme combinations for postoperative anti-edema therapy, though both treatments provided some benefit over the surgical baseline.
ser-SRC-004Prospective, randomized, double-blind, controlled clinical trial.
Sourceopen_in_newAl-Moraissi EA, Al-Zendani AA, Al-Selwi AM. Efficacy of Submucosal Injection of Chymotrypsin, Oral Serratiopeptidase or Oral Dexamethasone in Reducing Postoperative Complications Following Impacted Lower Third Molar Surgery. Front Oral Health. 2020;1:575176. doi:10.3389/froh.2020.575176. PMID:35047980.
Population: 60 patients undergoing impacted lower third molar extraction.
Dose protocol: Oral serratiopeptidase 10 mg versus submucosal chymotrypsin 5 mg versus oral dexamethasone 8 mg after third molar surgery (n=60)
Key findings: No statistically significant difference among the three treatments for pain, swelling, or mouth opening. Serratiopeptidase was comparable to dexamethasone.
Notes: Supports comparability with standard anti-inflammatory agents in narrow postoperative context.
Paper content
This double-blind randomized trial compared three different anti-inflammatory interventions after impacted lower third molar surgery in 60 patients. Submucosal chymotrypsin, oral serratiopeptidase, and oral dexamethasone were evaluated for postoperative pain, swelling, and mouth opening. No statistically significant differences were found among the three treatments on any endpoint. The result supports serratiopeptidase as comparably effective to dexamethasone in this narrow postoperative context but does not demonstrate superiority for any measured outcome. The study adds to the evidence base that serratiopeptidase has a role limited to short-term post-surgical anti-edema use.